Evidence map›Paper›PMID 33450312›Full record

ArticleAntiviral research2021

Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca

Fadhel A Alomar, Chengju Tian, Prasanta K Dash, JoEllyn M McMillan, Howard E Gendelman, Santhi Gorantla, Keshore R Bidasee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Fadhel A AlomarDepartment of Pharmacology and Toxicology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Saudi Arabia.
Chengju TianDepartments of Pharmacology and Experimental Neuroscience, USA.
Prasanta K DashDepartments of Pharmacology and Experimental Neuroscience, USA.
JoEllyn M McMillanDepartments of Pharmacology and Experimental Neuroscience, USA; Environment and Occupational Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Howard E GendelmanDepartments of Pharmacology and Experimental Neuroscience, USA.
Santhi GorantlaDepartments of Pharmacology and Experimental Neuroscience, USA.
Keshore R BidaseeDepartments of Pharmacology and Experimental Neuroscience, USA; Environment and Occupational Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Nebraska Redox Biology Center, Lincoln, NE, USA. Electronic address: kbidasee@unmc.edu.
Society on Neuroimmune Pharmacology · USNebraska Medical Center · USImam Abdulrahman Bin Faisal University · SA

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S · 2000 to 2021
$37.7M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
LASER ART for PrePR01AI158160 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2021 to 2025
$3.5M
Diastolic dysfunction in HIV infectionR56HL151602 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BIDASEE, KESHORE R, GORANTLA, SANTHI · 2020 to 2020
$586k
NHLBI NIH HHS R56 HL151602NIAID NIH HHS R01 AI158160NIDA NIH HHS P01 DA028555NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH115860
6 · The paper itself

Abstract

While muscle fatigue, pain and weakness are common co-morbidities in HIV-1 infected people, their underlying cause remain poorly defined. To this end, we evaluated whether the common antiretroviral drugs efavirenz (EFV), atazanavir (ATV) and ritonavir (RTV) could be a contributing factor by pertubating sarcoplasmic reticulum (SR) Ca

Indexed as

AlkynesAnimalsAnti-HIV AgentsAtazanavir SulfateBenzoxazinesCalciumCell LineCyclopropanesHomeostasisMiceMuscle, SkeletalMyoblastsRabbitsRitonavirRyanodineRyanodine Receptor Calcium Release ChannelAlkynesAnti-HIV AgentsAtazanavir SulfateBenzoxazinesCalciumCyclopropanesefavirenzRitonavirRyanodineRyanodine Receptor Calcium Release ChannelAtazanavirCa(2+) cyclingEfavirenzHIV-1RitonavirRyR1Sarcoplasmic reticulumSERCA1.Skeletal muscle weakness (dynapenia)

Identifiers

PMID33450312
PMCPMC8019157
OpenAlexW3119253618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.